NCT01522482

Brief Summary

Cardiovascular disease (CVD) is the greatest cause of morbidity and mortality in the UK. Abnormalities in the concentration and/or composition of lipoproteins (the lipid carrying particles), in particular low density lipoproteins (LDL) in circulation, is one of the most important physiological defects contributing to the development of CVD. The LDL cholesterol (LDLC) response to fatty acid change is in part mediated by the APOE genotype, with E4 individuals (25% of the UK population) being most responsive to changes in dietary fats, showing greater reductions when low levels of saturated fats or fish oils are consumed and greater increases when high levels of these fats are consumed. Therefore the aims of the present study is to understand the mechanism that regulates the higher LDLC response associated with saturated fatty acids and fish oil consumption in healthy men prospectively recruited based on their APOE genotype.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2009

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

January 26, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 31, 2012

Completed
Last Updated

February 2, 2012

Status Verified

January 1, 2012

Enrollment Period

9 months

First QC Date

January 26, 2012

Last Update Submit

January 31, 2012

Conditions

Keywords

fatty acidscardiovascular diseasegenotypeapoE

Outcome Measures

Primary Outcomes (1)

  • Impact of APOE genotype and dietary fat composition in plasma lipids

    3 months

Secondary Outcomes (1)

  • Cardiovascular disease risk factors

    3 months

Study Arms (3)

High saturated fat meal

EXPERIMENTAL
Dietary Supplement: High saturated fat meal

Saturated fatty acid and fish oils meal

EXPERIMENTAL

Equivalent to two portions of oily fish

Dietary Supplement: Saturated fatty acids and fish oil meal

High unsaturated fat meal

ACTIVE COMPARATOR

Provided a fatty acid profile representative of a typical UK diet

Dietary Supplement: High unsaturated fat meal

Interventions

High saturated fat mealDIETARY_SUPPLEMENT

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.

High saturated fat meal

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil. The dose of fish oils was equivalent to two portions of oily fish.

Saturated fatty acid and fish oils meal
High unsaturated fat mealDIETARY_SUPPLEMENT

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.

High unsaturated fat meal

Eligibility Criteria

Age18 Years - 70 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Gender Male
  • Age 18-70 years
  • Body Mass Index (BMI) \< 32 kg/m2
  • Plasma triglycerides 1-4 mmol/l
  • Plasma cholesterol \< 8 mmol/l
  • Glucose \< 7 mmol/l
  • Haemoglobin \> 11 g/dl
  • ApoE E3/E3, E3/E4

You may not qualify if:

  • Blood pressure \> 200/95 mmHg
  • Had suffered a myocardial infraction or stroke in previous 2 years.
  • Diabetes mellitus
  • Liver disease
  • Other endocrine disorders
  • Unstable angina
  • Familial hyperlipidaemia
  • Any dietary restrictions or an a weight reducing diet
  • On fatty acid supplements e.g. evening primrose oil or fish oils
  • Vigorous exercise e.g. competitive athletes
  • ApoE2/E2, apoE2/E3 and apoE2/E4
  • Any other parameter on which the investigators felt an individual was unsuitable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Food and Nutritional Sciences, University of Reading

Reading, United Kingdom

Location

Related Publications (2)

  • Calabuig-Navarro MV, Jackson KG, Kemp CF, Leake DS, Walden CM, Lovegrove JA, Minihane AM. A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s. Sci Rep. 2017 Mar 9;7:44119. doi: 10.1038/srep44119.

  • Calabuig-Navarro MV, Jackson KG, Walden CM, Minihane AM, Lovegrove JA. Apolipoprotein E genotype has a modest impact on the postprandial plasma response to meals of varying fat composition in healthy men in a randomized controlled trial. J Nutr. 2014 Nov;144(11):1775-80. doi: 10.3945/jn.114.197244. Epub 2014 Sep 17.

MeSH Terms

Conditions

Cardiovascular Diseases

Interventions

Fatty Acids

Intervention Hierarchy (Ancestors)

Lipids

Study Officials

  • Julie A Lovegrove, Professor

    University of Reading

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 26, 2012

First Posted

January 31, 2012

Study Start

March 1, 2009

Primary Completion

December 1, 2009

Study Completion

July 1, 2011

Last Updated

February 2, 2012

Record last verified: 2012-01

Locations